The Securities were sold without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and in reliance on similar exemptions under applicable state laws.

Entry into a Material Definitive Agreement. On August 5, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with a syndicate of existing and new healthcare investors (the “Investors”) for a private placement of: (i) 2,098,519 shares (the “Initial Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, at a purchase price of $56.00 per share; and (ii) pre-funded warrants (the…

Results of Operations and Financial Condition. On August 6, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three and six months ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under

Other Events. On August 6, 2026, the Company issued a press release announcing the pricing of the private placement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in

Other Events. On August 6, 2026, the Company issued a press release announcing the Merger Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Forward-Looking Statements Statements in this Current Report on Form 8-K about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited…

Entry into a Material Definitive Agreement. Merger Agreement On July 31, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Alkeus Pharmaceuticals, Inc., a Delaware corporation (“Alkeus”), Apex 2026 Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Shareholder Representative Services LLC, as the securityholders’ representative. Pursuant to the Merger Agreement, and…

Chief Commercial Officer — Aziz Mottiwala: Aziz Mottiwala is leaving his role as Chief Commercial Officer to pursue a new opportunity.

Entry into a Material Definitive Agreement. On July 6, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with iRenix Medical, Inc., a Delaware corporation (“iRenix”), Dolores Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”) and Fortis Advisors LLC, as the securityholders’ representative (the “Securityholders’ Representative”). Pursuant to the Merger Agreement, on July 6, 20…

Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in

Results of Operations and Financial Condition. On May 6, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under

Results of Operations and Financial Condition. On February 23, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under

Director — David E.I. Pyott: The company expanded its board and appointed David E.I. Pyott as a new director with significant responsibilities.

Results of Operations and Financial Condition. On November 4, 2025, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under

Results of Operations and Financial Condition. On August 6, 2025, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three and six months ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under

Results of Operations and Financial Condition. On May 1, 2025, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three months ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under

Entry into a Material Definitive Agreement. On March 12, 2025, Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, BofA Securities, Inc., and Barclays Capital Inc., acting as representatives of the underwriters named in the Underwriting Agreement (the “Underwriters”), relating to the sale of 2,808,988 shares of the Company’s common stock, par value $0.0001 per share (the “Offe…

Results of Operations and Financial Condition. On February 25, 2025, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under

Director — Rosemary Crane: Rosemary Crane resigned from the Board of Directors and entered into a consulting agreement with the company.

Entry into a Material Definitive Agreement On December 16, 2024, Tarsus Pharmaceuticals, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with Spectrum Terrace III LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company will lease approximately 59,626 square feet of office space located at 17700 Laguna Canyon Road, Irvine, California (the “Premises”). The Company intends to relocate its corporate headquarters to the Premises. The term of the…

Results of Operations and Financial Condition. On November 13, 2024, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three and nine months ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under

Chief Medical Officer — Elizabeth Yeu, M.D.: Dr. Elizabeth Yeu was promoted from a consulting role to Chief Medical Officer and resigned her board position.

Results of Operations and Financial Condition. On August 8, 2024, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three and six months ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under

Results of Operations and Financial Condition. On May 8, 2024, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three months ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under

Entry into a Material Definitive Agreement. On April 19, 2024, Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) entered into an agreement with funds managed by Pharmakon Advisors LP, BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent for the lenders, and the guarantors party to such agreement (the “Loan Agreement”). The Loan Agreement provides for an initial term loan in the principal amount of…